查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424834

基因组学市场：按技术、应用、最终用户、服务划分-全球预测（至2031年）

Genomics Market by Technology, Application, End User, Offering - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 320 Pages | 订单完成后即时交付

价格

到 2031 年，全球基因组学市场预计将达到 705.2 亿美元，2024 年至 2031 年复合年增长率为 11.1%。

经过广泛的二次和初步研究以及对市场情景的详细分析，本报告对关键行业驱动因素、限制因素、挑战和机会进行了分析。 基因组学市场的成长是由遗传患者病率上升、基因组学数据越来越多地融入临床工作流程、增加基因组学计画的资金和投资、扩大基因组学在医疗保健和製药中的应用所推动的。驱动因素包括研发支出的增加、降低定序成本并增加医疗保健支出。 然而，基因组学缺乏标准化方法以及对基因组学资料安全和隐私的担忧正在限制该市场的成长。

此外，个人化药物和基因治疗的日益普及预计将创造市场成长机会。 然而，缺乏熟练的生物资讯学和基因组学人才、基因组学技术的商业化和扩展给市场利益相关者带来了重大挑战。

本报告是基于对领先市场参与者在四年期间（2020-2024 年）的产品组合、区域影响力和关键策略发展的广泛评估，提供了竞争格局。 全球基因组学市场的主要参与者包括安捷伦科技公司（美国）、Bio-Rad Laboratories, Inc.（美国）、丹纳赫公司（美国）、赛默飞世尔科技公司（美国）、Illumina, Inc. （美国） )、QIAGEN N.V.（荷兰）、Pacific Biosciences of California, Inc.（美国）、Oxford Nanopore Technologies Plc.（英国）、Eppendorf SE（德国）、Myriad Genetics, Inc.（美国）、Revvity, Inc. （原PerkinElmer） , Inc. 美国）和华大基因有限公司（中国）。

在本报告研究的所有产品中，消耗品领域预计在预测期内复合年增长率最高。 此细分市场复合年增长率最高的原因是遗传疾病盛行率不断上升、基因检测的采用率增加以及消耗品而非设备的定期购买。 遗传疾病的日益普及推动了对基因检测的需求，从而推动了耗材的采用。 例如，根据美国MJH生命科学公司2022年发布的报告，全球每年约有30万个婴儿出生时患有镰状细胞疾病，全球近5%的人口受到镰状细胞疾病的影响。

在本报告调查的所有技术中，聚合□炼式反应 (PCR) 领域预计将在 2024 年占据基因组学市场的最大份额。 PCR 在临床诊断中的使用增加、PCR 技术的进步、基因组学研究的合作研究以及 PCR 在这些研究调查中的使用是促成该细分市场最大份额的一些因素。 产品的推出进一步提高了该细分市场的重要市场份额。 例如，2023 年 3 月，Bio-Rad Laboratories 推出了 PTC Tempo 96 和 PTC Tempo Deepwell 热循环仪，以优化定序、克隆和基因分型等 PCR 应用。

在本报告研究的所有应用中，诊断领域预计将在 2024 年占据基因组学市场的最大份额。 基因组学在肿瘤学、新生儿筛检和肝炎检测中的应用占据了这一领域的最大份额。 新生儿筛检是对新生儿进行的测试，旨在识别已知的遗传性疾病。 政府机构支持新生儿筛检，透过早期发现、诊断和介入来降低新生儿遗传疾病的发生率。 例如，2022年12月，英国政府投资超过1.106亿美元（1.05亿英镑）来加速新生儿罕见疾病的诊断速度。 此类举措在推动该细分市场的最大份额方面发挥关键作用。

在本报告研究的所有最终用户中，製药和生技公司领域预计在预测期内复合年增长率最高。 该领域复合年增长率最高的原因是製药和生物技术公司研发的增加、研究方法中基因组学利用率的提高以及生物技术公司数量的增加。 此外，慢性病的盛行率日益增加，加速了药物开发进程的需要，并进一步推动了製药公司采用基因组学。

对全球基因组学市场区域状况的详细分析提供了五个主要区域（北美、欧洲、亚太地区、拉丁美洲、中东和非洲）的详细定性和定量见解，并提供了关键国家覆盖范围。 到 2024 年，北美预计将占据基因组学市场的最大份额。 北美拥有许多专门从事基因组学研究的着名研究机构、大学和组织。 由于药物研发支出的增加和大公司的存在，该地区正在为癌症基因组学做出重大贡献。 例如，在加拿大，製药公司正在增加药物发现的研发支出，从而推动了对基因组学的需求。 例如，2020 年加拿大製药业的研发总支出预计在 18 亿美元至 24 亿美元之间，而 2019 年为 16 亿美元至 22 亿美元。 因此，研究机构的存在、遗传疾病检测的增加以及药品研发支出的增加支撑着最大的区域份额。

目录

第 1 章简介

第 2 章研究方法

第 3 章执行摘要

第 4 章市场洞察

  • 摘要
  • 影响市场成长的因素
    • 市场动态影响分析
    • 因素分析
  • 技术趋势
  • 基因体学市场：监理分析
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东/非洲
    • 基因治疗和基因组编辑的指南和规定
  • 价格分析
  • 波特五力分析

第 5 章基因体学市场评估：依产品

  • 摘要
  • 消耗品
  • 设备
  • 软体
  • 服务

第 6 章基因体市场评估：依技术

  • 摘要
  • 聚合□炼式反应 (PCR)
  • 定序
    • 次世代定序 (NGS)
    • 其他定序技术
  • 核酸萃取与纯化
  • 微阵列晶片
  • 其他技术

第 7 章基因体学市场评估：按应用

  • 摘要
  • 诊断
  • 药物发现与药物开发
  • 生命科学研究
    • 癌症研究
    • 干细胞研究
    • 其他生命科学研究
  • 其他用途

第 8 章基因体市场评估：按最终使用者

  • 摘要
  • 製药和生技公司
  • 医院/诊所
  • 诊断实验室
  • CRO（药物开发合约组织）
  • 学术/研究机构
  • 其他最终用户

第 9 章基因体市场评估：按地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 中东/非洲

第 10 章竞争分析

  • 简介
  • 主要成长策略
  • 竞争基准测试
  • 竞争对手仪表板
    • 行业领导者
    • 市场差异化因素
    • 领先企业
    • 新兴公司
  • 市占率分析
    • Thermo Fisher Scientific Inc.（美国）
    • Illumina, Inc.（美国）
    • Qiagen N.V.（荷兰）

第 11 章公司简介（公司概况、财务概况、产品组合、策略发展）

  • Thermo Fisher Scientific Inc.
  • Illumina, Inc
  • Qiagen N.V.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies plc
  • Eppendorf SE
  • Myriad Genetics, Inc.
  • Reevity, Inc.（Formerly PerkinElmer, Inc.）
  • BGI Genomics Co.,Ltd.

（註：包含前5名公司的SWOT分析）

第 12 章附录

Product Code: MRHC - 104157

Genomics Market by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction) Application (Drug Discovery, Diagnostic, Research) End User (Pharmaceutical, Hospital, Academic) Offering (Instrument, Consumable, Software)-Global Forecast to 2031

The global genomics market is projected to reach $70.52 billion by 2031, at a CAGR of 11.1% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the genomics market is driven by the rising prevalence of genetic diseases, the increasing incorporation of genomic data in clinical workflows, increasing funding and investments in genomics projects, the growing applications of genomics in the healthcare sector, rising pharmaceutical R&D expenditures, decreasing cost of sequencing, and increasing healthcare spending. However, the lack of standardized approaches in genomics and concerns over the security & privacy of genomic data restrain the growth of this market.

Moreover, the rising adoption of personalized medicines and gene therapies is expected to generate market growth opportunities. However, the shortage of skilled bioinformatics and genomics personnel and the commercialization and scaling of genomic technologies are major challenges for market stakeholders.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the global genomics market are Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Eppendorf SE (Germany), Myriad Genetics, Inc. (U.S.), Revvity, Inc. (Formerly PerkinElmer, Inc.) (U.S.), and BGI Genomics Co. Ltd (China).

Among all the offerings studied in this report, the consumables segment is projected to register the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to the increasing prevalence of genetic diseases, growing adoption of genetic testing, and recurring purchase of consumables over instruments. An increase in the prevalence of genetic disease cases has triggered the demand for genetic tests, which is driving the adoption of consumables. For instance, according to a report published by MJH Life Sciences (U.S.) in 2022, approximately 300,000 babies are born with sickle cell disease per year globally, and nearly 5% of the world's population is affected by the disease.

Among all the technologies studied in this report, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the genomics market. The increasing use of PCR in clinical diagnostics, technological advancements in PCR, collaborations for genomic research, and the use of PCR in these research studies are some of the factors contributing to the segment's largest share. Product launches further boost this segment's large market share. For instance, in March 2023, Bio-Rad Laboratories launched PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers to optimize PCR applications such as sequencing, cloning, and genotyping.

Among all the applications studied in this report, in 2024, the diagnostics segment is expected to account for the largest share of the genomics market. The use of genomics in oncology, newborn screening, and hepatitis testing is contributing to the largest share of the segment. Genomics is used in newborn screening, which are laboratory tests performed on newborn babies to identify known genetic diseases. Government agencies support newborn screening to reduce the incidence of genetic disorders among newborns through early detection, diagnosis, and intervention. For instance, in December 2022, the government of the U.K. invested more than USD 110.6 million (GBP 105 million) to speed up the rare disease diagnosis in newborns. Such initiatives play a vital role in driving the segment's largest share.

Among all the end users studied in this report, the pharmaceutical & biotechnology companies' segment is expected to record the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to the increasing research & development by pharmaceutical & biotechnology companies, the rising utilization of genomics for research processes, and an increasing number of biotechnology companies. Moreover, the rising incidence of chronic diseases has accelerated the need to expedite drug development processes, further propelling the adoption of genomics among pharmaceutical companies.

An in-depth analysis of the geographical scenario of the global genomics market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the genomics market. North America is home to numerous renowned research institutions, universities, and organizations dedicated to genomics research; the region has made significant contributions to cancer genomics, with rising pharmaceutical R&D expenditure and the presence of key players. For instance, R&D spending by pharmaceutical companies in Canada for drug discovery has increased, driving the demand for genomics. For instance, in 2020, total R&D expenditure in Canada's pharmaceutical sector was estimated at between USD 1.8 billion and USD 2.4 billion, compared to USD 1.6 billion and USD 2.2 billion in 2019. Thus, the presence of research institutes, rising testing for genetic disorders, and increasing pharmaceutical R&D expenditure is supporting the largest regional share.

Scope of the Report:

Genomics Market Assessment-by Offering

  • Systems
  • Consumables
  • Software
  • Services

Genomics Market Assessment-by Technology

  • Polymerase Chain Reaction (PCR)
  • Sequencing
    • NGS
    • Other Sequencing Technologies
  • Nucleic Acid Extraction and Purification
  • Microarray
  • Other Technologies

Note: Other sequencing technologies include pyrosequencing, degradome sequencing, sanger sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing.

Note: Other technologies include cell counting, transfection, and gene editing.

Genomics Market Assessment-by Application

  • Diagnostics
  • Drug Discovery & Development
  • Life Sciences Research
    • Cancer Research
    • Stem Cell Research
    • Other Life Sciences Research
  • Other Applications

Note: Other life sciences research applications include cardiovascular research, osteoporosis, immunology, neurobiology, cellular and molecular biology, and diabetes

Note: Other applications include agriculture, forensics, and environmental.

Genomics Market Assessment-by End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Other End Users

Note: Other end users include food & beverage companies, agriculture companies, and forensics.

Genomics Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Impact Analysis of Market Dynamics
      • 4.2.1.1. Rising Prevalence of Genetic Diseases and the Incorporation of Genomic Data in Clinical Workflows Driving Market Growth
      • 4.2.1.2. Concerns Over the Security & Privacy of Genomic Data Limiting the Adoption of Genomics Products
      • 4.2.1.3. Rising Adoption of Personalized Medicines and Gene Therapies
      • 4.2.1.4. Commercializing and Scaling Genomic Technologies Remain Major Challenges for Market Stakeholders
    • 4.2.2. Factor Analysis
  • 4.3. Technology Trends
  • 4.4. Genomics Market: Regulatory Analysis
    • 4.4.1. North America
      • 4.4.1.1. U.S.
      • 4.4.1.2. Canada
    • 4.4.2. Europe
      • 4.4.2.1. Shift From Pre-Approval to A Lifecycle Approach
      • 4.4.2.2. Classification Changes
      • 4.4.2.3. Stronger Supervision
      • 4.4.2.4. Clearer Rights and Responsibilities for Economic Operators
      • 4.4.2.5. Traceability/EUDAMED
      • 4.4.2.6. General Safety and Performance Requirements
      • 4.4.2.7. Performance Evaluation and Clinical Evidence
    • 4.4.3. Asia-Pacific
      • 4.4.3.1. China
      • 4.4.3.2. Japan
      • 4.4.3.3. India
    • 4.4.4. Latin America
    • 4.4.5. Middle East & Africa
    • 4.4.6. Guidelines and Regulations for Gene Therapy and Genome Editing
  • 4.5. Pricing Analysis
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Buyers
    • 4.6.2. Bargaining Power of Suppliers
    • 4.6.3. Threat of Substitutes
    • 4.6.4. Threat of New Entrants
    • 4.6.5. Degree of Competition

5. Genomics Market Assessment-by Offering

  • 5.1. Overview
  • 5.2. Consumables
  • 5.3. Instruments
  • 5.4. Software
  • 5.5. Services

6. Genomics Market Assessment-by Technology

  • 6.1. Overview
  • 6.2. Polymerase Chain Reaction (PCR)
  • 6.3. Sequencing
    • 6.3.1. Next-Generation Sequencing (NGS)
    • 6.3.2. Other Sequencing Technologies
  • 6.4. Nucleic Acid Extraction & Purification
  • 6.5. Microarray
  • 6.6. Other Technologies

7. Genomics Market Assessment-by Application

  • 7.1. Overview
  • 7.2. Diagnostics
  • 7.3. Drug Discovery & Development
  • 7.4. Life Sciences Research
    • 7.4.1. Cancer Research
    • 7.4.2. Stem Cell Research
    • 7.4.3. Other Life Sciences Research
  • 7.5. Other Applications

8. Genomics Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Pharmaceutical & Biotechnology Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Diagnostic Laboratories
  • 8.5. Contract Research Organizations (CROs)
  • 8.6. Academic & Research Institutes
  • 8.7. Other End Users

9. Genomics Market Assessment-by Geography

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Rest Of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Rest Of Asia-Pacific
  • 9.5. Latin America
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Share Analysis
    • 10.5.1. Thermo Fisher Scientific Inc. (U.S.)
    • 10.5.2. Illumina, Inc. (U.S.)
    • 10.5.3. Qiagen N.V. (Netherlands)

11. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)

  • 11.1. Thermo Fisher Scientific Inc.
  • 11.2. Illumina, Inc
  • 11.3. Qiagen N.V.
  • 11.4. Danaher Corporation
  • 11.5. Agilent Technologies, Inc.
  • 11.6. Bio-Rad Laboratories, Inc.
  • 11.7. Pacific Biosciences of California, Inc.
  • 11.8. Oxford Nanopore Technologies plc
  • 11.9. Eppendorf SE
  • 11.10. Myriad Genetics, Inc.
  • 11.11. Reevity, Inc. (Formerly PerkinElmer, Inc.)
  • 11.12. BGI Genomics Co.,Ltd.

(Note: SWOT Analysis of Top 5 Companies is Provided)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports
  • Table 1 Regulatory Authorities Governing Genomic Products, by Country/Region
  • Table 2 Guidelines for Gene Therapy and Genome Editing, by Regulatory Body
  • Table 3 Pricing: Genomics Instruments
  • Table 4 Pricing: Genomics Consumables
  • Table 5 Average Selling Prices: Genomics Instruments
  • Table 6 Average Selling Prices: Genomics Consumables
  • Table 7 Global Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 8 Global Genomics Consumables Market, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Genomics Instruments Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Genomics Software Market, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Genomics Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 13 Global Genomics Market for Polymerase Chain Reaction, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Genomics Market for Sequencing, by Type, 2022-2031 (USD Million)
  • Table 15 Global Genomics Market for Sequencing, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Genomics Market for Next-Generation Sequencing, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Genomics Market for Other Sequencing Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global Genomics Market for Nucleic Acid Extraction and Purification, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Global Genomics Market for Microarrays, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Genomics Market for Other Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 22 Global Genomics Market for Diagnostics, by Country/Region, 2022-2031 (USD Million)
  • Table 23 Global Genomics Market for Drug Discovery and Development, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global Genomics Market for Life Sciences Research, by Type, 2022-2031 (USD Million)
  • Table 25 Global Genomics Market for Life Sciences Research, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Number of New Cancer Cases, by Region, 2020 Vs. 2040 (In Million)
  • Table 27 Global Genomics Market for Cancer Research, by Country/Region, 2022-2031 (USD Million)
  • Table 28 Global Genomics Market for Stem Cell Research, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Genomics Market for Other Life Sciences Research, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Genomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 32 Global Genomics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Genomics Market for Hospitals & Clinics, by Country/Region, 2022-2031 (USD Million)
  • Table 34 Global Genomics Market for Diagnostic Laboratories, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Genomics Market for Contract Research Organizations (CROs) by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Genomics Market for Academic & Research Institutes, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Genomics Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 39 North America: Genomics Market, by Country, 2022-2031 (USD Million)
  • Table 40 North America: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 41 North America: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 42 North America: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 43 North America: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 44 North America: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 45 North America: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 46 U.S.: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 47 U.S.: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 48 U.S.: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 49 U.S.: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 50 U.S.: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 51 U.S.: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 52 Canada: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 53 Canada: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 54 Canada: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 55 Canada: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 56 Canada: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 57 Canada: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 58 Europe: Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 59 Europe: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 60 Europe: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 61 Europe: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 62 Europe: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 63 Europe: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 64 Europe: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 65 Germany: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 66 Germany: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 67 Germany: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 68 Germany: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 69 Germany: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 70 Germany: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 71 France: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 72 France: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 73 France: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 74 France: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 75 France: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 76 France: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 77 U.K.: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 78 U.K.: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 79 U.K.: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 80 U.K.: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 81 U.K.: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 82 U.K.: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 83 Italy: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 84 Italy: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 85 Italy: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 86 Italy: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 87 Italy: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 88 Italy: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 89 Spain: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 90 Spain: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 91 Spain: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 92 Spain: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 93 Spain: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 94 Spain: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 95 Rest of Europe: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 96 Rest of Europe: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 97 Rest of Europe: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 98 Rest of Europe: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 99 Rest of Europe: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 100 Rest of Europe: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 101 Asia-Pacific: Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 102 Asia-Pacific: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 103 Asia-Pacific: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 104 Asia-Pacific: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 105 Asia-Pacific: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 106 Asia-Pacific: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 107 Asia-Pacific: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 108 China: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 109 China: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 110 China: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 111 China: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 112 China: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 113 China: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 114 Japan: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 115 Japan: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 116 Japan: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 117 Japan: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 118 Japan: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 119 Japan: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 120 India: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 121 India: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 122 India: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 123 India: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 124 India: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 125 India: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 126 Rest of Asia-Pacific: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 127 Rest of Asia-Pacific: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 128 Rest of Asia-Pacific: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 129 Rest of Asia-Pacific: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 130 Rest of Asia-Pacific: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 131 Rest of Asia-Pacific: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 132 Latin America: Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 133 Latin America: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 134 Latin America: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 135 Latin America: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 136 Latin America: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 137 Latin America: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 138 Latin America: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 139 Brazil: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 140 Brazil: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 141 Brazil: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 142 Brazil: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 143 Brazil: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 144 Brazil: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 145 Mexico: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 146 Mexico: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 147 Mexico: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 148 Mexico: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 149 Mexico: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 150 Mexico: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 151 Rest of Latin America: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 152 Rest of Latin America: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 153 Rest of Latin America: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 154 Rest of Latin America: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 155 Rest of Latin America: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 156 Rest of Latin America: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 157 Middle East & Africa: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 158 Middle East & Africa: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 159 Middle East & Africa: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 160 Middle East & Africa: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 161 Middle East & Africa: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 162 Middle East & Africa: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 163 Recent Developments, by Company, 2020-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referred for This Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply Side & Dem and Side)
  • Figure 6 Market Sizing and Growth Forecast Approach
  • Figure 7 Global Genomics Market, by Offering, 2024 Vs. 2031 (USD Million)
  • Figure 8 Global Genomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global Genomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 10 Global Genomics Market, by End User, 2024 Vs. 2031 (USD Million)
  • Figure 11 Genomics Market, by Geography
  • Figure 12 Impact Analysis of Market Dynamics
  • Figure 13 Healthcare Expenditure as A Percentage of GDP in Major Countries, 2015 Vs. 2020
  • Figure 14 Global Pharmaceutical R&D Expenditure, 2012-2022 (USD Billion)
  • Figure 15 Estimated Number of New Cancer Cases, by Region, 2020 Vs. 2030 (in Thousand)
  • Figure 16 Percentage of FDA Approvals for Personalized Medicine, 2015-2021
  • Figure 17 USFDA Regulatory Pathways for Genomic Products
  • Figure 18 EU Regulatory Pathway IVDR 2017/746
  • Figure 19 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
  • Figure 20 Porter's Five Forces Analysis
  • Figure 21 Global Genomics Market, by Offering, 2024 Vs. 2031 (USD Million)
  • Figure 22 Global Genomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 23 Global Genomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 24 Global Pharmaceutical R&D Expenditure, 2014-2026 (USD Billion)
  • Figure 25 Cancer Incidence Cases, 2020 Vs. 2040
  • Figure 26 Global Genomics Market, by End User, 2024 Vs. 2031 (USD Million)
  • Figure 27 Global Pharmaceutical R&D Spending, 2012-2026 (USD Billion)
  • Figure 28 Global Genomics Market Assessment, by Region, 2024 Vs. 2031 (USD Million)
  • Figure 29 North America: Genomics Market Snapshot
  • Figure 30 Europe: Genomics Market Snapshot
  • Figure 31 Asia-Pacific: Genomics Market Snapshot
  • Figure 32 Latin America: Genomics Market Snapshot
  • Figure 33 Key Growth Strategies Adopted by Leading Players, 2020-2023
  • Figure 34 Genomics Market: Competitive Benchmarking, by Offering
  • Figure 35 Genomics Market: Competitive Benchmarking, by Geography
  • Figure 36 Competitive Dashboard: Genomics Market
  • Figure 37 Global Genomics Market Share Analysis, by Key Players
  • Figure 38 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
  • Figure 39 Illumina, Inc.: Financial Overview (2022)
  • Figure 40 Qiagen N.V.: Financial Overview (2022)
  • Figure 41 Danaher Corporation: Financial Overview (2022)
  • Figure 42 Agilent Technologies, Inc.: Financial Overview (2023)
  • Figure 43 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
  • Figure 44 Pacific Biosciences of California, Inc.: Financial Overview (2022)
  • Figure 45 Oxford Nanopore Technologies plc.: Financial Overview (2022)
  • Figure 46 Eppendorf SE: Financial Overview (2022)
  • Figure 47 Myriad Genetics, Inc.: Financial Overview (2022)
  • Figure 48 PerkinElmer, Inc.: Financial Overview (2022)
  • Figure 49 BGI Genomics Co.,Ltd.: Financial Overview (2022)